Free Trial

LivaNova (LIVN) Competitors

$60.47
+0.43 (+0.72%)
(As of 05/29/2024 ET)

LIVN vs. ITGR, CNMD, HAE, TMDX, INMD, SLNO, BLFS, AXGN, OM, and MASI

Should you be buying LivaNova stock or one of its competitors? The main competitors of LivaNova include Integer (ITGR), CONMED (CNMD), Haemonetics (HAE), TransMedics Group (TMDX), InMode (INMD), Soleno Therapeutics (SLNO), BioLife Solutions (BLFS), AxoGen (AXGN), Outset Medical (OM), and Masimo (MASI). These companies are all part of the "medical" sector.

LivaNova vs.

Integer (NYSE:ITGR) and LivaNova (NASDAQ:LIVN) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Integer has a net margin of 6.01% compared to Integer's net margin of -2.68%. Integer's return on equity of 13.59% beat LivaNova's return on equity.

Company Net Margins Return on Equity Return on Assets
Integer6.01% 11.25% 5.69%
LivaNova -2.68%13.59%7.06%

Integer currently has a consensus price target of $128.00, suggesting a potential upside of 5.47%. LivaNova has a consensus price target of $66.20, suggesting a potential upside of 9.48%. Given Integer's higher possible upside, analysts plainly believe LivaNova is more favorable than Integer.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Integer
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71
LivaNova
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40

In the previous week, Integer and Integer both had 5 articles in the media. Integer's average media sentiment score of 1.16 beat LivaNova's score of 0.83 indicating that LivaNova is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Integer
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
LivaNova
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

99.3% of Integer shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 2.0% of Integer shares are owned by company insiders. Comparatively, 0.3% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

LivaNova received 3 more outperform votes than Integer when rated by MarketBeat users. Likewise, 68.78% of users gave LivaNova an outperform vote while only 63.41% of users gave Integer an outperform vote.

CompanyUnderperformOutperform
IntegerOutperform Votes
376
63.41%
Underperform Votes
217
36.59%
LivaNovaOutperform Votes
379
68.78%
Underperform Votes
172
31.22%

Integer has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.

Integer has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integer$1.60B2.55$90.65M$2.8941.99
LivaNova$1.19B2.76$17.55M-$0.60-100.78

Summary

Integer beats LivaNova on 10 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LIVN vs. The Competition

MetricLivaNovaElectromedical equipment IndustryMedical SectorNASDAQ Exchange
Market Cap$3.27B$3.22B$5.13B$8.05B
Dividend YieldN/A1.68%2.83%3.97%
P/E Ratio-100.789.67171.0518.36
Price / Sales2.7670.282,443.5179.27
Price / Cash13.8574.8735.2731.30
Price / Book2.684.335.524.59
Net Income$17.55M$87.88M$105.72M$213.84M
7 Day Performance1.84%1.22%0.64%0.31%
1 Month Performance8.47%9.19%2.55%3.12%
1 Year Performance37.96%-5.09%5.38%6.91%

LivaNova Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ITGR
Integer
2.2117 of 5 stars
$121.83
+0.2%
$128.00
+5.1%
+51.0%$4.08B$1.63B42.1610,500Insider Selling
CNMD
CONMED
4.9117 of 5 stars
$73.10
-2.5%
$102.50
+40.2%
-37.3%$2.25B$1.24B28.014,000Dividend Announcement
Short Interest ↑
HAE
Haemonetics
4.2099 of 5 stars
$88.64
-1.6%
$108.67
+22.6%
+5.1%$4.51B$1.31B38.713,657Insider Selling
Analyst Revision
High Trading Volume
TMDX
TransMedics Group
2.4137 of 5 stars
$137.53
+0.4%
$119.00
-13.5%
+101.3%$4.53B$241.62M-404.50584Positive News
INMD
InMode
2.1214 of 5 stars
$18.45
-3.4%
$32.80
+77.8%
-41.8%$1.55B$492.05M8.74581Short Interest ↑
SLNO
Soleno Therapeutics
4.2445 of 5 stars
$41.17
-4.0%
$60.33
+46.5%
+717.0%$1.38BN/A-15.3633Gap Down
BLFS
BioLife Solutions
0.326 of 5 stars
$21.09
-3.6%
$23.67
+12.2%
-4.0%$970.77M$143.27M-14.85409Short Interest ↑
Gap Down
AXGN
AxoGen
2.38 of 5 stars
$6.11
-1.5%
$10.67
+74.6%
-24.5%$267.04M$163.73M-12.22426Positive News
Gap Down
OM
Outset Medical
1.4545 of 5 stars
$3.99
+2.3%
$5.42
+35.8%
-82.3%$206.36M$130.38M-1.18480Positive News
MASI
Masimo
4.1794 of 5 stars
$124.75
-1.5%
$138.71
+11.2%
-19.3%$6.62B$2.05B84.865,200Short Interest ↓
Positive News

Related Companies and Tools

This page (NASDAQ:LIVN) was last updated on 5/30/2024 by MarketBeat.com Staff

From Our Partners